Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR Get Rating) have earned a consensus rating of Buy from the six analysts that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $15.00. <\/p>\n
A number of equities research analysts have recently weighed in on the company. Cantor Fitzgerald assumed coverage on Jasper Therapeutics in a report on Monday, February 28th. They set an overweight rating and a $10.00 price target on the stock. Credit Suisse Group cut their price target on Jasper Therapeutics from $15.00 to $10.00 and set an outperform rating on the stock in a report on Friday, February 25th. Finally, Zacks Investment Research raised Jasper Therapeutics from a sell rating to a hold rating in a report on Thursday, January 20th.<\/p>\n
JSPR stock traded down $0.13 during midday trading on Tuesday, reaching $2.72. The company had a trading volume of 62,997 shares, compared to its average volume of 85,363. The stocks 50 day moving average price is $3.58. Jasper Therapeutics has a fifty-two week low of $2.70 and a fifty-two week high of $18.88. <\/p>\n
Jasper Therapeutics Company Profile (Get Rating)<\/p>\n
Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation.<\/p>\n
See Also<\/p>\n<\/p>\n
Receive News & Ratings for Jasper Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jasper Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.<\/p>\n
<\/p>\n
Read more: Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR Get Rating) have earned a consensus rating of Buy from the six analysts that are presently covering the stock, Marketbeat Ratings reports. Continue reading
\nJasper Therapeutics, Inc. (NASDAQ:JSPR) Receives Average Recommendation of Buy from Analysts - Defense World<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"